Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Primary Myelofibrosis 2Myeloproliferative Disorders 2Carcinoma, Non-Small-Cell Lung 2Thrombocytosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Inhibition, Psychological 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1B-cell Malignancies 1Anemia, Refractory, with Excess of Blasts 1

Interventions

zanubrutinib 1tislelizumab 1tirabrutinib 1obinutuzumab 1itacitinib 1idelalisib 1INCB039110 16-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
B-cell Malignancies × INCB039110 × 1 year × Clear all
NCT01905813 2026-05-11

Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

Incyte Corporation

Phase 1 Completed
121 enrolled
Lymphoid

B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡